develop
effect
tumor
vaccin
major
task
cancer
immunotherapi
ideal
tumor
vaccin
abl
elicit
tumorspecif
cell
capabl
recogn
elimin
tumor
cell
recent
year
identif
kind
potenti
tumor
vaccin
exosom
brought
new
light
prepar
ideal
tumor
vaccin
exosom
kind
cellfre
vaccin
popul
nanomet
size
membran
vesicl
secret
mani
type
cell
dendrit
cell
dc
b
lymphocyt
tumor
cell
two
type
exosom
dcderiv
exosom
tumorderiv
exosom
show
capabl
induc
tumorspecif
cell
respons
protect
antitumor
immun
anim
model
exosomebas
vaccin
even
clinic
trial
cancer
immunotherapi
howev
immunogen
potenti
effici
exosomesbas
tumor
vaccin
remain
improv
obtain
satisfactori
cur
effect
shown
vaccin
exosom
bear
tumor
antigen
combin
immunoadjuv
eg
cpg
induc
augment
antitumor
effect
adjuv
especi
cytokin
proven
help
tumor
immunotherapi
therefor
investig
effici
tumorderiv
exosom
incorpor
cytokin
tumor
cell
previous
identifi
factor
also
promis
vaccin
adjuv
elicit
varieti
effect
immun
respons
includ
stimul
natur
killer
cell
nk
tb
lymphocyt
produc
high
level
promot
cell
prolifer
enhanc
kill
activ
cytotox
lymphocyt
ctl
nk
cell
facilit
dc
matur
exert
proinflammatori
properti
induc
releas
chemokin
chemoattract
dc
cell
polymorphonuclear
cell
other
previous
shown
potent
antitumor
immun
induc
cytotox
cell
nk
cell
potenti
faslmedi
cytotox
inhibit
tumor
angiogenesi
therefor
pleiotrop
activ
suggest
play
import
role
induct
antitumor
immun
studi
investig
efficaci
specif
exosom
deriv
genemodifi
tumor
cell
infect
tumor
cell
wellknown
human
colon
adenocarcinoma
cell
line
produc
high
level
cea
recombin
adenoviru
express
human
obtain
exosom
contain
bioactiv
demonstr
enhanc
dc
function
vitro
upregul
express
costimulatori
molecul
enhanc
product
promot
immmunostimulatori
capac
dc
also
effect
chemoattract
dc
cell
importantli
superior
ceaspecif
ctl
gener
lymphocyt
deriv
hlaa
cea
cancer
patient
lymphocyt
incub
dc
compar
gener
lymphocyt
incub
dc
puls
exosom
includ
exosom
deriv
cell
exo
adlacz
genet
modifi
cell
exolacz
find
suggest
potent
induct
antitumor
immun
tradit
exosom
prepar
exosom
tumor
cell
geneticali
modifi
cytokin
adjuv
simpl
feasibl
strategi
develop
exosomesbas
tumor
vaccin
cea
cea
lovo
cea
human
tapdefici
cell
transform
cell
obtain
american
type
cultur
collect
manassa
va
maintain
correspond
cultur
medium
accord
supplier
specif
cell
free
mycoplasma
hlaa
cea
peptid
ylsganlnl
irrelev
hlaa
coronaviru
sarscov
spike
protein
peptid
rlnevaknl
synthes
accord
standard
solid
phase
synthesi
method
purifi
hplc
puriti
ident
peptid
determin
analyt
hplc
mass
spectrometri
analysi
respect
patient
requir
give
written
inform
consent
particip
studi
patient
histolog
confirm
diagnosi
stage
iii
carcinoma
colon
entri
criteria
follow
confirm
hlaa
pcrbase
dna
type
one
lambda
inc
ca
usa
posit
cea
express
defin
immunohistochem
analysi
chemotherapi
radiotherapi
week
studi
studi
four
cea
patient
two
male
two
femal
select
construct
use
adenovir
vector
system
stratagen
la
jolla
ca
briefli
dna
fragment
encod
activ
form
signal
peptid
ntermin
synthes
insert
express
vector
pshuttlecmv
xho
ecor
v
site
result
plasmid
design
linear
cotransform
compet
escherichia
coli
cell
supercoil
circular
electropor
recombin
adenovir
vector
dna
isol
select
posit
clone
linear
transfect
cell
pack
recombin
adenoviru
mb
mammalian
transfect
kit
stratagen
accord
manufactur
standard
protocol
sever
cycl
propag
recombin
adenovirus
purifi
cscl
band
final
yield
measur
describ
previous
express
confirm
elisa
assay
medic
biolog
laboratori
co
ltd
nagaoya
japan
cultur
supernat
cell
biolog
activ
determin
abil
induc
product
peripher
blood
mononuclear
cell
pbmc
presenc
con
describ
previous
pbmc
plate
cellswel
supplement
uml
penicillin
mgl
streptomycin
mm
lglutamin
mm
sodium
pyruv
decompl
fc
final
volum
togeth
mgl
con
sampl
either
supernat
exosom
cultur
incub
h
supernat
analyz
human
elisa
r
system
minneapoli
mn
exosom
purifi
describ
previous
h
transfect
cell
without
adenoviru
moi
cell
wash
three
time
pb
cultur
complet
dmem
medium
h
cultur
supernat
collect
isol
exolacz
exo
exosom
purif
exosom
suspend
pb
layer
onto
discontinu
densiti
cushion
sucros
wv
mm
hepesnaoh
gml
centrifug
h
exosom
accumul
interfac
collect
wash
pb
exosom
protein
measur
bradford
assay
biorad
endotoxin
contamin
exosom
analyz
limulu
amebocyt
lysat
biowhittak
walkersvil
md
less
exosom
protein
western
blot
assay
compon
exosom
perform
describ
previous
us
primari
antibodi
use
anticea
clone
neomark
westinghous
dr
fremont
ca
usa
antitransferrin
receptor
tfr
santa
cruz
biotechnolog
inc
santa
cruz
ca
soldano
ferron
roswel
park
cancer
institut
ny
usa
pbmc
prolifer
assay
conduct
describ
minor
modif
briefli
pbmc
per
well
ad
roundbottom
cultur
plate
cultur
exosom
final
volum
supplement
fc
h
presenc
pha
thymidin
ad
cell
addit
h
cell
harvest
onto
filter
count
liquid
scintil
count
wallac
dsa
usa
parallel
h
cultur
supernat
harvest
test
product
elisa
endogen
cambridg
monocytederiv
dc
healthi
individu
gener
describ
ngml
nm
cayman
chemic
ann
arbor
mi
use
induc
dc
matur
immatur
dc
idc
day
five
cultur
exosom
lp
medium
addit
h
resuspend
pb
dc
stain
fitclabel
pelabel
pelabel
percplabel
antihladr
analyz
facscan
parallel
supernat
harvest
measur
concentr
use
commerci
avail
elisa
kit
endogen
cambridg
mlr
conduct
previous
describ
briefli
idc
day
five
collect
incub
exosom
medium
lp
h
use
stimul
irradi
rad
allogen
cell
isol
magnet
bead
miltenyi
biotec
auburn
ca
stimul
irradi
dc
differ
responderstimul
ratio
day
cultur
thymidin
ad
well
incorpor
radioact
measur
h
later
chemoattract
dc
cell
respons
exosom
investig
transwel
cultur
plate
describ
minor
modif
briefli
cell
popul
posit
purifi
pbmc
use
magnet
bead
miltenyi
biotec
auburn
ca
puriti
cell
judg
flow
cytometri
analysi
cellsml
purifi
cell
idc
day
five
matur
dc
mdc
day
seven
medium
ad
upper
chamber
transwel
chamber
incub
h
number
cell
chemoattract
bottom
well
count
fac
result
express
chemotact
index
quotient
number
chemoattract
cell
presenc
exosomeschemoattract
cell
presenc
medium
pbmc
hlaa
posit
cancer
patient
isol
ficollhypaqu
densiti
gradient
centrifug
day
five
dc
cultur
dcwell
puls
exosom
plate
h
cultur
medium
cocultur
autolog
cell
ratio
final
volum
mlwell
presenc
ngml
recombin
human
peprotech
inc
rocki
hill
nj
ctl
induc
previous
describ
day
final
stimul
function
stimul
lymphocyt
evalu
releas
assay
cytotox
assay
hlaa
tetram
assay
proimmun
oxford
biobusi
centr
littlemor
park
releas
assay
stimul
cell
cell
puls
supernat
effector
cell
cocultur
nativ
test
level
elisa
assay
r
system
cytotox
assay
perform
use
standard
releas
assay
describ
cell
obtain
neg
select
four
round
vitro
stimul
target
ctl
activ
lovo
cell
target
cell
harvest
wash
count
label
target
cell
amersham
arlington
height
il
label
target
cell
cellswel
wash
three
time
use
cocultur
cell
variou
e
ratio
assay
perform
triplic
result
express
comparison
two
group
conduct
student
test
multipl
comparison
done
oneway
anova
follow
fisher
least
signific
differ
analysi
pairwis
comparison
done
perform
nonparametr
u
test
experi
repeat
least
twice
p
valu
less
consid
signific
cell
genet
modifi
differ
moi
secret
differ
level
differ
time
maxim
product
modifi
cell
observ
h
modif
moi
fig
concentr
rang
pgml
moi
pgml
moi
cell
transfect
control
adenoviru
adlacz
secret
fig
moreov
supernat
modifi
cell
could
induc
pbmc
releas
fig
suggest
supernat
function
activ
result
show
recombin
adenoviru
success
construct
cell
transfect
growth
rate
cell
affect
transfect
data
shown
isol
cultur
supernat
transfect
cell
heterogen
popul
nm
vesicl
diamet
observ
electron
microscopi
data
shown
consist
morpholog
typic
exosom
western
blot
analysi
show
exo
exolacz
contain
cea
tfr
detect
fig
result
indic
sort
contain
tumor
antigen
cea
hsp
pbmc
incub
significantli
secret
higher
level
incub
control
exosom
fig
p
indic
bioactiv
could
enhanc
releas
pbmc
presenc
con
also
test
prolifer
secret
pbmc
found
augment
prolifer
fig
p
secret
pbmc
presenc
pha
fig
p
effect
observ
absenc
pha
meanwhil
control
exosom
includ
exo
exolacz
could
demonstr
similar
effect
indic
effect
ascrib
sort
genet
modif
report
exosom
deriv
differ
origin
may
differ
effect
dc
matur
examin
effect
dc
observ
could
effici
upregul
express
hladr
dc
fig
increas
cytokin
product
dc
fig
p
control
dc
matur
expos
dc
lp
found
dc
secret
compar
induc
lp
fig
result
mlr
also
reveal
dc
potent
induc
cell
prolifer
dc
treat
exo
exolacz
fig
p
stimulatorrespond
ratio
data
suggest
could
induc
phenotyp
function
matur
dc
dc
acquir
potent
capabl
stimul
cell
prolifer
test
whether
chemotact
effect
dc
cell
first
perform
dosedepend
experi
test
chemotact
activ
matur
dc
mdc
found
chemotact
index
increas
concentr
rang
exo
exolacz
chemotact
effect
even
higher
concentr
fig
examin
chemoattract
idc
mdc
exo
exolacz
result
show
signific
chemotact
effect
immun
cell
differ
extent
fig
indic
could
markedli
chemoattract
cell
dc
consist
report
indirect
direct
chemotact
effect
dc
cell
therefor
data
suggest
superior
advantag
convent
exosom
deriv
parent
tumor
cell
conduct
vitro
ctl
induct
experi
test
possibl
efficaci
appli
tumor
immunotherapi
purifi
ceaposit
cell
contain
cea
isol
dc
pbmc
hlaa
cea
cancer
patient
test
effici
dc
induct
ceaspecif
ctl
ceaspecif
ctl
judg
lysi
cea
target
cell
product
upon
cea
epitopepuls
stimul
cea
epitopespecif
tetram
stain
result
target
cell
lysi
show
ctl
induc
dc
potent
kill
cell
cea
fig
p
induc
exopuls
exolaczpuls
dc
less
effici
kill
lovo
cell
cea
fig
togeth
suggest
observ
lysi
ceaspecif
hlaa
manner
correspondingli
ctl
induc
dc
produc
stimul
induc
exopuls
exolaczpuls
dc
fig
p
tetram
stain
assay
cell
detect
cycl
vitro
restimul
dc
exopuls
dc
exolaczpuls
dc
fig
note
pbmc
stimul
dc
load
exhibit
higher
percentag
lymphocyt
compar
stimul
dc
load
exo
exolacz
fig
suggest
could
promot
develop
cell
studi
ceaspecif
ctl
could
readili
gener
three
four
hlaa
cea
cancer
patient
studi
prepar
new
kind
exosom
name
exosom
deriv
genemodifi
tumor
cell
bioactiv
success
incorpor
promot
pbmc
prolifer
secret
cytokin
chemoattract
dc
cell
vitro
enhanc
phenotyp
function
matur
dc
effici
convent
exosom
importantli
dc
quit
potent
induc
tumor
antigenspecif
ctl
vitro
cocultur
autolog
lymphocyt
therefor
demonstr
distinct
properti
convent
prepar
exosom
deriv
parent
tumor
cell
thu
may
repres
new
approach
design
effect
tumor
vaccin
futur
recombin
cytokin
gmcsf
immunoadjuv
use
cancer
treatment
system
toxic
limit
use
howev
modifi
tumor
cell
cytokin
gene
decreas
system
toxic
local
secret
cytokin
cytokineload
microspher
clinic
potenti
develop
system
antitumor
immun
strategi
natur
incorpor
cytokin
exosom
may
better
simpli
mix
cytokin
exosom
antitumor
immun
induct
cytokin
modifi
exosom
combin
advantag
exosomesbas
cancer
immunotherapi
cytokinemedi
gene
therapi
therefor
incorpor
cytokin
exosom
may
import
approach
improv
effici
exosomesbas
vaccin
report
cea
vaccin
could
augment
coadministr
gmcsf
howev
local
administr
cytokin
rapidli
redistribut
circul
thu
lead
mani
undesir
sideeffect
quick
clearanc
membranebound
cytokin
propos
appropri
adjuv
vaccin
restrict
administr
site
natur
sort
bioactiv
exosom
make
membran
compart
suppos
slowli
releas
result
vitro
experi
demonstr
contain
cea
potent
capabl
induc
pbmc
prolifer
secret
cytokin
chemoattract
dc
cell
promot
phenotyp
function
matur
dc
induc
ceaspecif
ctl
therefor
multipl
effect
suggest
may
potenti
function
well
induc
potent
specif
antitumor
immun
vivo
need
extens
investig
although
studi
directli
appli
anim
model
vivo
due
speci
barrier
suggest
might
serv
immunoadjuv
multipl
advantag
induc
antitumor
immun
vivo
first
chemoattract
dc
cell
thu
potenti
accumul
immun
cell
local
site
administr
secondli
contain
may
induc
releas
lead
final
elimin
tumor
cell
thirdli
augment
releas
promot
cell
prolifer
support
idea
immun
molecul
influenc
local
environ
way
would
benefici
patient
therefor
reason
predict
may
function
effect
induct
antitumor
immun
administr
local
vivo
identif
presenc
exosom
provid
critic
insight
improv
tumorderiv
exosom
exosom
express
cytokin
adjuv
thu
becom
one
attract
strategi
combat
cancer
use
rel
simpl
strategi
incorpor
cytokin
chemokin
adhes
molecul
costimulatori
molecul
combin
exosom
obtain
cancer
vaccin
provid
suffici
immunogen
molecul
effect
cancer
immunotherapi
futur
trial
